|
07.11.2024 14:59:50
|
Ligand Pharmaceuticals Boosts FY24 Outlook - Update
(RTTNews) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and revenue guidance for fiscal 2024.
For fiscal 2024, the company now projects core adjusted earnings in a range of $5.50 to $5.70 per share on revenues between $160 million to $165 million.
Previously, the company expected core adjusted earnings in the range of $5.00 to $5.50 per share on revenues between $140 million to $157 million.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.39 per share on revenues of $156.38 million for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Nachrichten zu Ligand Pharmaceuticals Inc
Analysen zu Ligand Pharmaceuticals Inc
3 neue Aktien 📈 im BX Musterportfolio: Trane Techn., Nasdaq Inc & Manhattan Ass. mit François Bloch
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Trane Technologies
NEU✅ Nasdaq Inc
NEU✅ Manhattan Associates Inc
inklusive Rebalancing:
❌ Eli Lilly and Company
❌ Intesa Sanpaolo
❌ Unicredit
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Ligand Pharmaceuticals Inc | 157.66 | 18.62% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
US-Börsen legen zu -- SMI schliesst leichter -- DAX setzt Rekordserie fort -- Asiens Börsen: Nur Tokio zum Handelsschluss im PlusDer heimische Leitindex gab zur Wochenmitte nach. Der deutsche Leitindex erklomm neue Rekorde. An der Wall Street geht es nach oben. Die Märkte in Fernost zeigten sich am Mittwoch mit uneiniger Tendenz.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |